PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Zhu, Andrew X.
TI  - RAM Fails to Improve OS as Second-Line Treatment for Hepatocellular Cancer
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 18--20
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/18.2.short
4100  - http://mdc.sagepub.com/content/14/36/18.2.full
AB  - As second-line therapy for hepatocellular carcinoma, ramucirumab did not improve overall survival compared with placebo in a phase 3 randomized study, but benefit was observed in a selected population with an elevated baseline level of alpha-fetoprotein. The results of the randomized, phase 3 Ramucirumab Second-Line Treatment in Patients With Hepatocellular Carcinoma After First-Line Therapy With Sorafenib study [REACH; NCT01140347] are discussed in this article.